Last updated on February 2019

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer


Brief description of study

This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma.

SECONDARY OBJECTIVES:

I. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to objective response rate (complete [CR] and partial [PR]), stable disease and progression.

II. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to severe toxicity interval.

III. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to colostomy-free survival.

IV. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to overall survival.

V. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to toxicity.

OUTLINE: Patients who received standard CMT are randomized to 1 of 2 arms.

ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients undergo observation.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.

Clinical Study Identifier: NCT03233711

Contact Investigators or Research Sites near you

Start Over

Jennifer A. Dorth

Mercy Cancer Center-Elyria
Elyria, OH United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.